B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients

BACKGROUND: B cell depletion with rituximab (RTX) is approved for treatment of rheumatoid arthritis (RA) and ANCA-associated vasculitides (AAV). Recently, RTX has been shown to be effective in AAV maintenance therapy, but an optimal RTX treatment schedule is unknown and the time to B cell repopulati...

Descripción completa

Detalles Bibliográficos
Autores principales: Thiel, Jens, Rizzi, Marta, Engesser, Marie, Dufner, Ann-Kathrin, Troilo, Arianna, Lorenzetti, Raquel, Voll, Reinhard E., Venhoff, Nils
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5437549/
https://www.ncbi.nlm.nih.gov/pubmed/28521808
http://dx.doi.org/10.1186/s13075-017-1306-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5437549/
https://www.ncbi.nlm.nih.gov/pubmed/28521808
http://dx.doi.org/10.1186/s13075-017-1306-0

Ejemplares similares